New follow-up research on baricitinib for type 1 diabetes addresses a crucial question: what happens after the drug is stopped? The original BANDIT trial showed that 48 weeks of oral baricitinib helped preserve beta-cell function in people with recently diagnosed type 1 diabetes. However, new follow-up research examines participants through …
Read More »Why Scientists Are Taking Another Look at the BCG Vaccine for Type 1 Diabetes
For more than 100 years, the Bacillus Calmette-Guérin (BCG) vaccine has been used worldwide to help prevent tuberculosis. However, researchers are now exploring another possible role for this familiar vaccine. Recent studies suggest that the BCG vaccine may play a role in treating type 1 diabetes by modifying the immune …
Read More »Teaching Muscles to Make Insulin: Could Gene Therapy Rewrite the Future of Type 1 Diabetes?
For more than a century, insulin therapy has remained the cornerstone of treatment for type 1 diabetes. While continuous glucose monitors, insulin pumps, and automated insulin delivery systems have dramatically improved diabetes management, they still do not replace the body’s natural ability to regulate blood sugar. As a result, researchers …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.